Alibaba
BABA
Netflix
NFLX
Broadcom
AVGO
Salesforce
CRM
Microsoft
MSFT
US Stock MarketDetailed Quotes
CHRS Coherus BioSciences
- 1.035
- -0.005-0.48%
Trading Mar 11 10:28 ET
119.95MMarket Cap4.14P/E (TTM)
1.121High0.950Low1.04MVolume1.030Open1.040Pre Close1.09MTurnover0.91%Turnover Ratio4.14P/E (Static)115.89MShares2.64052wk High-0.91P/B118.41MFloat Cap0.66052wk Low--Dividend TTM114.41MShs Float38.100Historical High--Div YieldTTM16.43%Amplitude0.660Historical Low1.043Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Coherus BioSciences Stock Forum
Net income (loss) for the fourth quarter of 2024 was a net loss of $50.7 million, or $(0.44) per share on a diluted basis, compared to a net loss of $79.7 million, or $(0.71) per share on a diluted basis for the same period in 2023.
Net income for the year ended December 31, 2024 was $28.5 million, or $0.25 per share on a diluted basis, compared to a net loss of $237.9 million, or $(2.53) per share on a diluted basis for year ended December 31, 202...
If you do not vote, its as good as voting against.
gov/Archives/ed...
Top Watch for Monday 1/27
$HOLO (1.56) Inv. Hammer Fri
$HEPA (.19c) Big move com...
📊⚡️📊
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Wednesday, 22nd January at 7:00 am
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
– Antitumor activity was observed across both viral and non-viral etiologies –
– Data support continued...
No comment yet